Jaguar Health vs Sol-gel Technologies
Sol-gel Technologies is the larger business, with $19.4m of revenue in fiscal 2025 against $11.5m for Jaguar Health (1.7 times as much). Sol-gel Technologies grew faster (68.0% against -1.5%). Sol-gel Technologies kept more of each dollar of sales as profit: a net margin of -31.6% against -465.4%.
| Latest fiscal year | Jaguar HealthJAGX, 2025 | Sol-gel TechnologiesSLGL, 2025 |
|---|---|---|
| Revenue | $11.5m | $19.4m |
| Revenue growth | -1.5% | 68.0% |
| Net income | −$53.6m | −$6.1m |
| Operating margin | -398.8% | -38.9% |
| Net margin | -465.4% | -31.6% |
| Return on equity | — | -23.7% |
| Free cash flow | −$23.7m | $275,000 |
| Cash | $968,000 | $11.0m |
| Total debt | $42.5m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $439,515 | $184m |
| Price vs our value range | — | — |
| Moat score | 32 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 49 buys, 0 sales |